drugset
drugset / Trial / NCT03272009

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

NCT03272009 ↗

Phase 1 Completed 73 enrolled Enyo Pharma CPR Pharma Services Pty Ltd, Australia · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B. This Phase 1b study is designed primarily to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of EYP001a in chronically HBV infected subjects.

Timeline

Start
2017-09-21
Primary completion
2018-07-30
Completion
2018-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EYP001a Unknown — Oral
Comparator Entecavir Small molecule — Oral
Background Peginterferon alfa-2a Protein / enzyme biologic — Subcutaneous

Indications

chronic hepatitis B virus infection